Genexine, Inc. (095700.KQ)
KRW 5590.0
(-3.79%)
KRW 5590.0
(-3.79%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -40.87 Billion KRW | -24.9% |
| 2022 | -29.54 Billion KRW | -33.22% |
| 2021 | -22.17 Billion KRW | 45.76% |
| 2020 | 47.99 Billion KRW | 7.66% |
| 2019 | 6.56 Billion KRW | -9.36% |
| 2018 | -29.11 Billion KRW | -67.21% |
| 2017 | -15.57 Billion KRW | 14.57% |
| 2016 | -27.64 Billion KRW | -703.81% |
| 2015 | 8.69 Billion KRW | 0.0% |
| 2012 | 2.12 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -5.49 Billion KRW | 44.92% |
| 2024 Q1 | -11.38 Billion KRW | 14.68% |
| 2023 Q2 | -10.75 Billion KRW | -6.13% |
| 2023 FY | - KRW | -24.9% |
| 2023 Q4 | -1.42 Billion KRW | 90.2% |
| 2023 Q3 | -14.57 Billion KRW | -35.58% |
| 2023 Q1 | -10.13 Billion KRW | 16.67% |
| 2022 Q4 | -12.15 Billion KRW | -64.12% |
| 2022 FY | - KRW | -33.22% |
| 2022 Q1 | 270.07 Million KRW | 102.05% |
| 2022 Q3 | -7.4 Billion KRW | 9.59% |
| 2022 Q2 | -8.19 Billion KRW | -3133.87% |
| 2021 Q1 | 11.66 Billion KRW | 198.57% |
| 2021 FY | - KRW | 45.76% |
| 2021 Q2 | -10.82 Billion KRW | -192.83% |
| 2021 Q3 | -7.48 Billion KRW | 30.84% |
| 2021 Q4 | -13.14 Billion KRW | -75.56% |
| 2020 Q3 | -11.09 Billion KRW | -23.21% |
| 2020 FY | - KRW | 7.66% |
| 2020 Q2 | -9 Billion KRW | -110.02% |
| 2020 Q4 | -11.83 Billion KRW | -6.63% |
| 2020 Q1 | -4.28 Billion KRW | 65.7% |
| 2019 Q2 | -13.09 Billion KRW | -7.35% |
| 2019 FY | - KRW | -9.36% |
| 2019 Q4 | -12.5 Billion KRW | -183.44% |
| 2019 Q3 | -4.41 Billion KRW | 66.33% |
| 2019 Q1 | -12.2 Billion KRW | 0.0% |
| 2018 FY | - KRW | -67.21% |
| 2017 FY | - KRW | 14.57% |
| 2016 FY | - KRW | -703.81% |
| 2015 FY | - KRW | 0.0% |
| 2013 Q3 | -199.78 Million KRW | 0.0% |
| 2012 Q3 | 538.23 Million KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 76.272% |
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | -555.659% |
| BINEX Co., Ltd. | 10.87 Billion KRW | 475.993% |
| Bioneer Corporation | 10.04 Billion KRW | 507.022% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | -9236.642% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | -110.803% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | 4.484% |
| Helixmith Co., Ltd | -53 Billion KRW | 22.877% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 158.324% |
| Medy-Tox Inc. | 32.69 Billion KRW | 225.016% |
| Peptron, Inc. | -12.65 Billion KRW | -223.134% |
| Amicogen, Inc. | 13.95 Billion KRW | 392.967% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | 596.721% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 42.736% |
| ALTEOGEN Inc. | 440.04 Million KRW | 9389.596% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 139.21% |
| SillaJen, Inc. | -17.35 Billion KRW | -135.575% |
| JETEMA, Co., Ltd. | 11 Billion KRW | 471.357% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | -267.112% |
| Genomictree Inc. | -6.33 Billion KRW | -545.597% |
| MedPacto, Inc. | -32.6 Billion KRW | -25.36% |
| D&D Pharmatech | -9.05 Billion KRW | -351.298% |
| EASY BIO,Inc. | 24.32 Billion KRW | 268.062% |
| GI Innovation, Inc. | -51.33 Billion KRW | 20.363% |